ERAS Intrinsic Valuation and Fundamental Analysis - Erasca Inc - Alpha Spread

Erasca Inc
NASDAQ:ERAS

Watchlist Manager
Erasca Inc Logo
Erasca Inc
NASDAQ:ERAS
Watchlist
Price: 2.97 USD 2.77% Market Closed
Market Cap: 810.3m USD
Have any thoughts about
Erasca Inc?
Write Note

Intrinsic Value

ERAS's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one ERAS stock under the Base Case scenario is 1.18 USD. Compared to the current market price of 2.97 USD, Erasca Inc is Overvalued by 60%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ERAS Intrinsic Value
1.18 USD
Overvaluation 60%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Erasca Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ERAS based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about ERAS?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Erasca Inc

Provide an overview of the primary business activities
of Erasca Inc.

What unique competitive advantages
does Erasca Inc hold over its rivals?

What risks and challenges
does Erasca Inc face in the near future?

Has there been any significant insider trading activity
in Erasca Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Erasca Inc.

Provide P/S
for Erasca Inc.

Provide P/E
for Erasca Inc.

Provide P/OCF
for Erasca Inc.

Provide P/FCFE
for Erasca Inc.

Provide P/B
for Erasca Inc.

Provide EV/S
for Erasca Inc.

Provide EV/GP
for Erasca Inc.

Provide EV/EBITDA
for Erasca Inc.

Provide EV/EBIT
for Erasca Inc.

Provide EV/OCF
for Erasca Inc.

Provide EV/FCFF
for Erasca Inc.

Provide EV/IC
for Erasca Inc.

Show me price targets
for Erasca Inc made by professional analysts.

What are the Revenue projections
for Erasca Inc?

How accurate were the past Revenue estimates
for Erasca Inc?

What are the Net Income projections
for Erasca Inc?

How accurate were the past Net Income estimates
for Erasca Inc?

What are the EPS projections
for Erasca Inc?

How accurate were the past EPS estimates
for Erasca Inc?

What are the EBIT projections
for Erasca Inc?

How accurate were the past EBIT estimates
for Erasca Inc?

Compare the revenue forecasts
for Erasca Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Erasca Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Erasca Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Erasca Inc compared to its peers.

Compare the P/E ratios
of Erasca Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Erasca Inc with its peers.

Analyze the financial leverage
of Erasca Inc compared to its main competitors.

Show all profitability ratios
for Erasca Inc.

Provide ROE
for Erasca Inc.

Provide ROA
for Erasca Inc.

Provide ROIC
for Erasca Inc.

Provide ROCE
for Erasca Inc.

Provide Gross Margin
for Erasca Inc.

Provide Operating Margin
for Erasca Inc.

Provide Net Margin
for Erasca Inc.

Provide FCF Margin
for Erasca Inc.

Show all solvency ratios
for Erasca Inc.

Provide D/E Ratio
for Erasca Inc.

Provide D/A Ratio
for Erasca Inc.

Provide Interest Coverage Ratio
for Erasca Inc.

Provide Altman Z-Score Ratio
for Erasca Inc.

Provide Quick Ratio
for Erasca Inc.

Provide Current Ratio
for Erasca Inc.

Provide Cash Ratio
for Erasca Inc.

What is the historical Revenue growth
over the last 5 years for Erasca Inc?

What is the historical Net Income growth
over the last 5 years for Erasca Inc?

What is the current Free Cash Flow
of Erasca Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Erasca Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Erasca Inc

Current Assets 418m
Cash & Short-Term Investments 408.4m
Other Current Assets 9.6m
Non-Current Assets 107.7m
Long-Term Investments 51.8m
PP&E 51.5m
Other Non-Current Assets 4.4m
Current Liabilities 24.9m
Accounts Payable 2.1m
Accrued Liabilities 22.6m
Other Current Liabilities 155k
Non-Current Liabilities 49.8m
Other Non-Current Liabilities 49.8m
Efficiency

Earnings Waterfall
Erasca Inc

Revenue
0 USD
Operating Expenses
-148m USD
Operating Income
-148m USD
Other Expenses
-10.3m USD
Net Income
-158.3m USD

Free Cash Flow Analysis
Erasca Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ERAS Profitability Score
Profitability Due Diligence

Erasca Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

31/100
Profitability
Score

Erasca Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

ERAS Solvency Score
Solvency Due Diligence

Erasca Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score
70/100
Solvency
Score

Erasca Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ERAS Price Targets Summary
Erasca Inc

Wall Street analysts forecast ERAS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ERAS is 4.66 USD with a low forecast of 3.03 USD and a high forecast of 7.35 USD.

Lowest
Price Target
3.03 USD
2% Upside
Average
Price Target
4.66 USD
57% Upside
Highest
Price Target
7.35 USD
147% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ERAS?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for ERAS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about ERAS dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

ERAS Price
Erasca Inc

1M 1M
+7%
6M 6M
+41%
1Y 1Y
+27%
3Y 3Y
-85%
5Y 5Y
-81%
10Y 10Y
-81%
Annual Price Range
2.97
52w Low
1.67
52w High
3.28
Price Metrics
Average Annual Return -37.87%
Standard Deviation of Annual Returns 48.95%
Max Drawdown -93%
Shares Statistics
Market Capitalization 802.7m USD
Shares Outstanding 272 817 984
Percentage of Shares Shorted 9.13%

Competitive Landscape

Ownership

ERAS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Erasca Inc Logo
Erasca Inc

Country

United States of America

Industry

Biotechnology

Market Cap

802.7m USD

Dividend Yield

0%

Description

Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The company is headquartered in San Diego, California and currently employs 123 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm is engaged in oncology and RAS targeting to create therapies and combination regimens for the treatment of cancer. Its product candidates are ERAS-007 and ERAS-601, which together comprises its MAPKlamp. In addition, it also includes two discovery programs, ERAS-9 and ERAS-11, small molecule inhibitor programs targeting SOS1 and MYC, respectively. Its MAPKlamp is an approach targeting upstream and downstream nodes in the RAS/MAPK pathway designed to shut down, or clamp, the signaling of various oncogenic drivers, such as RTKs, NF1, RAS, RAF, and MEK alterations trapped in between any nodes involving this pathway. With its MAPKlamp approach, it induces tumor regression in RAS/MAPK pathway-driven cancers, while also blocking the escape routes that lead to tumor resistance.

Contact

CALIFORNIA
San Diego
10835 Road To The Cure, Suite 140
+18584656511.0
www.erasca.com

IPO

2021-07-15

Employees

123

Officers

See Also

Discover More
What is the Intrinsic Value of one ERAS stock?

The intrinsic value of one ERAS stock under the Base Case scenario is 1.18 USD.

Is ERAS stock undervalued or overvalued?

Compared to the current market price of 2.97 USD, Erasca Inc is Overvalued by 60%.

Back to Top